USEFULNESS OF SERUM MICRORNAS AS BIOMARKERS FOR PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

被引：0
|
作者：
Blakley, Caroline [1 ]
Nelson, Benjamin [2 ]
Qarooni, Shatha [3 ]
Lee, Wai Han [3 ]
Tryggestad, Jeanie [3 ]
Short, Kevin [3 ]
Palle, Sirish Kumar [3 ]
机构：
[1] Univ Oklahoma, Hlth & Sci Ctr, Norman, OK USA
[2] Harold Hamm Diabet Ctr HHDC, Norman, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, OUHSC, Dept Pediat, Norman, OK USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
829
引用
收藏
页码：S626 / S626
页数：1
相关论文
共 50 条
  • [1] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,
  • [2] Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Liu, Huan
    Yerevanian, Armen
    Westerhoff, Maria
    Hastings, Margaret H.
    Guerra, Justin Ralph Baldovino
    Zhao, Meng
    Svensson, Katrin J.
    Cai, Bishuang
    Soukas, Alexander A.
    Rosenzweig, Anthony
    DIABETES, 2024, 73 (02) : 260 - 279
  • [3] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [4] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [5] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [6] Circulating vesicle microRNAs for metabolic dysfunction-associated steatotic liver disease (MASLD) staging and progression towards liver cancer
    Izquierdo-Sanchez, Laura
    Lapitz, Ainhoa
    Simao, Andre
    Iturbe-Rey, Santiago
    Arrese, Marco
    Oliveira, Claudia P.
    Allende, Ignacio Aguirre
    Echeveste, Ainhoa
    Jimenez-Aguero, Raul
    Eizaguirre, Emma
    Arnold, Jorge
    Alba, Carmen M. Del Prado
    Martinez-Chantar, Maria Luz
    Schoonjans, Kristina
    Aspichueta, Patricia
    Perugorria, Maria Jesus
    Bujanda, Luis
    Rodrigues, Pedro M.
    Banales, Jesus Maria
    JOURNAL OF HEPATOLOGY, 2024, 80 : S536 - S536
  • [7] INSULIN RESISTANCE IS A PREDICTOR OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASLD-ASSOCIATED FIBROSIS
    Kim, David S.
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Le, Alexander
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1657 - S1657
  • [8] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [9] Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Markowska, Julia
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Dragan, Magdalena
    Kondracka, Adrianna
    Gondek, Ewa
    Oniszczuk, Tomasz
    Oniszczuk, Anna
    MOLECULES, 2024, 29 (22):
  • [10] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
12345